Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

BACKGROUND: Semaglutide is a glucagon-like peptide-1 (GLP-1) analog treatment for type 2 diabetes (T2D) available in subcutaneous (s.c.) and oral formulations. Two cardiovascular (CV) outcomes trials showed that in subjects with T2D at high risk of CV events there were fewer major adverse CV events...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cardiovasc Diabetol
Main Authors: Husain, Mansoor, Bain, Stephen C., Holst, Anders Gaarsdal, Mark, Thomas, Rasmussen, Søren, Lingvay, Ildiko
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2020
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7526237/
https://ncbi.nlm.nih.gov/pubmed/32998732
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12933-020-01106-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados